Company news from the 05/08/07 News Brief

Share this article:
E-Healthcare Solutions (EHS) announced that Ascend Media Healthcare has signed an exclusive representation agreement that names EHS as the sole provider of on-line advertising for Ascend Media’s Healthcare portfolio of medical and healthcare websites. The agreement calls for EHS to centrally sell and deliver advertising campaigns to the online publications in the healthcare division, including Cardiology Review, The American Journal of Managed Care, Pharmacy Times, Internal Medicine World Report, Physician’s Money Digest, Surgical Rounds, Family Practice Recertification and Resident & Staff Physician. Bayer HealthCare Pharmaceuticals , a US-based pharmaceuticals unit of Bayer HealthCare, and Intendis , a US-based affiliate of Bayer Schering Pharma AG, Germany, announced that they will jointly promote Yaz (drospirenone/ethinyl estradiol) as a treatment for moderate acne in women who desire an oral contraceptive for birth control. The agreement went into effect on May 1, as part of an overall strategy to introduce dermatologists to the anti-acne benefits of Yaz. Investigators will present new clinical data demonstrating the efficacy of Yaz in the treatment of moderate acne at the American College of Obstetricians and Gynecologists (ACOG) annual clinical meeting in San Diego. Yaz is the only oral contraceptive approved for the treatment of premenstrual dysphoric disorder (PMDD) in women who desire an oral contraceptive for birth control. PMDD is a condition in which women's premenstrual symptoms are severe enough to impact activities, work or relationships. In January, 2007, Yaz received FDA approval as a treatment for moderate acne in women who desire an oral contraceptive for birth control.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.